Are there clinical trials combining immunotherapy with other treatments for Esophageal Cancer

Clinical Trials Combining Immunotherapy with Other Treatments for Esophageal Cancer

Yes, there are several important clinical trials and treatment approaches combining immunotherapy with other therapies for esophageal cancer. Let me explain what's currently being used and studied.

Current Standard Approaches (Based on Evidence)

According to the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers (Version 4.2025), immunotherapy is increasingly being combined with chemotherapy in first-line treatment:

For Advanced Esophageal Cancer:

Checkpoint inhibitors added to chemotherapy are now recommended for patients with advanced disease who have a PD-L1 CPS (Combined Positive Score) ≥1. This means:

• Your tumor is tested to see if it expresses PD-L1 (a protein that helps cancer hide from the immune system)
• If the score is high enough, immunotherapy drugs are added to standard chemotherapy
• This combination has shown better outcomes than chemotherapy alone

Specific Drug Combinations Being Used:

According to NCCN Guidelines, tislelizumab (an immunotherapy drug) is being combined with chemotherapy:

• Tislelizumab + Cisplatin + Paclitaxel - used for advanced esophageal squamous cell carcinoma
• This combination was studied in the RATIONALE-306 trial, which showed improved results compared to chemotherapy alone

Special Situation: MSI-H/dMMR Tumors

If your tumor has MSI-H (microsatellite instability-high) or dMMR (mismatch repair deficient) status, immunotherapy becomes even more important:

According to NCCN Guidelines, patients with these tumor characteristics may benefit from:

• Nivolumab + Ipilimumab (two immunotherapy drugs working together) followed by nivolumab alone
• Pembrolizumab (another immunotherapy option)
• Tremelimumab + Durvalumab (for neoadjuvant therapy before surgery)

These combinations can be used before surgery (neoadjuvant) or as part of perioperative treatment.

Perioperative Immunotherapy (Before and After Surgery)

For patients undergoing surgery, NCCN Guidelines recommend:

• FLOT + Durvalumab - chemotherapy (FLOT regimen) combined with durvalumab immunotherapy for patients with PD-L1 CPS ≥1
• Nivolumab after surgery - recommended after preoperative chemoradiation if there is residual disease found at surgery

How These Combinations Work

The clinical reasoning: Immunotherapy drugs (called checkpoint inhibitors) work by "releasing the brakes" on your immune system, allowing it to recognize and attack cancer cells. When combined with chemotherapy:

• Chemotherapy damages cancer cells and makes them more visible to the immune system
• Immunotherapy helps your immune system recognize and destroy those damaged cells
• Together, they often work better than either treatment alone

Questions to Ask Your Oncology Team

Since clinical trials and treatment recommendations are constantly evolving, here are specific questions to discuss with your care team:

1. Has my tumor been tested for PD-L1 status and MSI-H/dMMR status? These tests determine if I'm a candidate for immunotherapy combinations.

2. Based on my specific tumor characteristics and stage, which immunotherapy combinations would be appropriate for my case?

3. Are there clinical trials available at your institution or nearby that I might be eligible for? (You can also search ClinicalTrials.gov)

4. What are the expected benefits and side effects of combining immunotherapy with my proposed chemotherapy regimen?

5. If I'm having surgery, would perioperative immunotherapy be recommended for me?

6. How will my response to treatment be monitored, and how often will imaging be done?

Where to Find More Information

• ClinicalTrials.gov - Search for "esophageal cancer immunotherapy" to find active trials you might be eligible for
• NCCN Guidelines - Your oncologist uses these evidence-based recommendations
• American Cancer Society - Provides patient-friendly information about immunotherapy

Important Context

The field of esophageal cancer treatment is evolving rapidly. The 2025 NCCN Guidelines show that immunotherapy combinations are becoming standard care for many patients, particularly those with advanced disease or specific tumor characteristics. However, the "best" approach for YOUR specific situation depends on:

• Your tumor type (adenocarcinoma vs. squamous cell carcinoma)
• Your tumor's biomarker status (PD-L1, MSI-H/dMMR, HER2)
• Your stage of disease
• Your overall health and ability to tolerate treatment
• Whether you're a candidate for surgery

Your multidisciplinary oncology team (medical oncologist, surgeon, radiation oncologist, and pathologist) should review your specific case to determine the optimal combination for you.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.